| Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases. | |
| | |
MedLine Citation:
|
PMID: 20807192 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Although glucocorticosteroids are still the first line of treatment for chronic asthma, over the last two decades great advances have been made in understanding the pathogenesis of asthma that enabled the identification of new therapeutic targets for asthma treatment. The interleukin (IL) 5: eosinophil axis is a hallmark pathway of allergic inflammation that has received much attention. Indeed, IL-5 is known to regulate eosinophil differentiation, proliferation, priming and activation. Therefore, therapeutic agents targeting IL-5 have been generated. In this review we will discuss the effects of IL-5 on eosinophils and outline the signaling mechanism involved in IL-5-mediated effects. Furthermore, recent results from clinical trials targeting IL-5 in asthma and hypereosinophilic syndrome will be discussed and an overview of newly developed patents aimed to target IL-5 will be reviewed. |
| | |
Authors:
|
Miguel L Stein; Ariel Munitz |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Recent patents on inflammation & allergy drug discovery Volume: 4 ISSN: 1872-213X ISO Abbreviation: Recent Pat Inflamm Allergy Drug Discov Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-09-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101309297 Medline TA: Recent Pat Inflamm Allergy Drug Discov Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 201-9 Citation Subset: IM |
Affiliation:
|
Pulmonary and Allergy Institute, Assaf-Harofeh Medical Center, Zerifin, Israel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current prospective of anti-IL-4, -IL-9, and -IL-13 therapies in allergic disease.
Next Document: TNF-alpha antagonism in severe asthma?